Literature DB >> 17972508

Expression of p53 and p21 and the clinical response for hyperthermochemoradiotherapy in patients with squamous cell carcinoma of the esophagus.

Mayumi Ishida1, Masaru Morita, Hiroshi Saeki, Takefumi Ohga, Noriaki Sadanaga, Masayuki Watanabe, Yoshihiro Kakeji, Yoshihiko Maehara.   

Abstract

BACKGROUND: The p53 and p21 genes are closely related to sensitivity to chemoradiotherapy. PATIENTS AND METHODS: The expressions of the p53 and p21 genes were immunohistochemically examined in 32 patients with esophageal cancer, who underwent an esophagectomy after hyperthermochemoradiotherapy (HCRT). The significance of the expression of these genes for the effect of HCRT was evaluated.
RESULTS: HCRT was markedly effective (grade 3 response: no residual viable cancer cells) in 12 cases (38%). The incidences of the grade 3 were 67% and 20% in the cases with a positive and negative p21 expression, respectively (p=0.0213). A multivariate analysis revealed the p21 expression to be a significant independent factor associated with the histological effects. None of the 10 patients with p53-positive and p21-negative tumors showed a grade 3 response, while 55% showed grade 3 response in other combination groups (p < 0.05).
CONCLUSION: The combination of p53 and p21 expressions in biopsy findings can thus predict the histological effectiveness of HCRT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17972508

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

Review 1.  Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

Authors:  Hiroshi Saeki; Yuichiro Nakashima; Yoko Zaitsu; Yasuo Tsuda; Yuta Kasagi; Koji Ando; Yu Imamura; Kippei Ohgaki; Shuhei Ito; Yasue Kimura; Akinori Egashira; Eiji Oki; Masaru Morita; Yoshihiko Maehara
Journal:  Surg Today       Date:  2015-03-05       Impact factor: 2.549

2.  RUNX3 reverses cisplatin resistance in esophageal squamous cell carcinoma via suppression of the protein kinase B pathway.

Authors:  De-Jun Li; Mo Shi; Zhou Wang
Journal:  Thorac Cancer       Date:  2016-06-20       Impact factor: 3.500

3.  Clinical and Prognostic Implications of P21 (WAF1/CIP1) Expression in Patients with Esophageal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Junbo Wu; Liang Liu; Feng Wu; Li Qiu; Ming Luo; Qing Ke; Xinzhou Deng; Zhiguo Luo
Journal:  Dis Markers       Date:  2020-01-07       Impact factor: 3.434

Review 4.  Function of p21 and its therapeutic effects in esophageal cancer.

Authors:  Lei Wang; Huiqiong Han; Lin Dong; Zehua Wang; Yanru Qin
Journal:  Oncol Lett       Date:  2020-12-20       Impact factor: 2.967

5.  Correlation among 16 biological factors [p53, p21(waf1), MIB-1 (Ki-67), p16(INK4A), cyclin D1, E-cadherin, Bcl-2, TNF-α, NF-κB, TGF-β, MMP-7, COX-2, EGFR, HER2/neu, ER, and HIF-1α] and clinical outcomes following curative chemoradiation therapy in 10 patients with esophageal squamous cell carcinoma.

Authors:  Shino Shibata-Kobayashi; Hideomi Yamashita; Kae Okuma; Kenshiro Shiraishi; Hiroshi Igaki; Kuni Ohtomo; Keiichi Nakagawa
Journal:  Oncol Lett       Date:  2013-01-11       Impact factor: 2.967

6.  Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus.

Authors:  Tomonori Nakanoko; Hiroshi Saeki; Masaru Morita; Yuichiro Nakashima; Koji Ando; Eiji Oki; Takefumi Ohga; Yoshihiro Kakeji; Yasushi Toh; Yoshihiko Maehara
Journal:  Ann Surg Oncol       Date:  2013-09-25       Impact factor: 5.344

Review 7.  Esophageal Cancer in Golestan Province, Iran: A Review of Genetic Susceptibility and Environmental Risk Factors.

Authors:  Mahin Gholipour; Farhad Islami; Gholamreza Roshandel; Masoud Khoshnia; Abbas Badakhshan; Abdolvahab Moradi; Reza Malekzadeh
Journal:  Middle East J Dig Dis       Date:  2016-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.